Autoimmunity in common variable immunodeficiency: epidemiology, pathophysiology and management
Introduction: Common variable immunodeficiency (CVID) comprises a large heterogeneous
group of patients with primary antibody deficiency. Areas covered: The affected patients are …
group of patients with primary antibody deficiency. Areas covered: The affected patients are …
Approach to the management of autoimmunity in primary immunodeficiency
Primary immunodeficiency diseases (PID s) consist of a genetically heterogeneous group of
immune disorders that affect distinct elements of the immune system. PID patients are more …
immune disorders that affect distinct elements of the immune system. PID patients are more …
Autoimmunity and its association with regulatory T cells and B cell subsets in patients with common variable immunodeficiency
Background Common variable immunodeficiency (CVID) is one of the most prevalent
symptomatic primary immunodeficiencies (PIDs), which manifests a wide clinical variability …
symptomatic primary immunodeficiencies (PIDs), which manifests a wide clinical variability …
The use of immunoglobulin therapy in primary immunodeficiency diseases
G Azizi, H Abolhassani… - … Metabolic & Immune …, 2016 - benthamdirect.com
Immunoglobulin therapy represents a lifesaving intervention for many patients with primary
immunodeficiency (PID). Antibody defects represent approximately half of the well-known …
immunodeficiency (PID). Antibody defects represent approximately half of the well-known …
Measurement of health-related quality of life in primary antibody-deficient patients
Background: Primary immunodeficiency diseases are a group of disorders that result from a
variety of defects of the immune system. Primary antibody deficiencies (PADs) are the most …
variety of defects of the immune system. Primary antibody deficiencies (PADs) are the most …
Managing patients with side effects and adverse events to immunoglobulin therapy
Immunoglobulin therapy has not only served as a lifesaving approach for the prevention and
treatment of infections in primary and secondary immunodeficiency diseases, but has also …
treatment of infections in primary and secondary immunodeficiency diseases, but has also …
Non-allergic Hypersensitivity Reactions to Immunoglobulin Preparations in Antibody Deficiencies: What Role for Anti-IgA IgG and Complement Activation?
A Collet, DP de Chambure, E Moitrot, G Breyne… - Clinical Reviews in …, 2024 - Springer
The presence of IgG anti-IgA in the serum of primary immunodeficiency (PID) patients has
long been considered responsible for hypersensitivity (HS) to immunoglobulin preparations …
long been considered responsible for hypersensitivity (HS) to immunoglobulin preparations …
Primary immunodeficiencies: a decade of shifting paradigms, the current status and the emergence of cutting-edge therapies and diagnostics
M Ebadi, A Aghamohammadi… - Expert review of clinical …, 2015 - Taylor & Francis
A shift has occurred in the diagnostic and therapeutic modalities considered for patients with
primary immunodeficiency diseases (PIDs). Early diagnosis remains the mainstay in …
primary immunodeficiency diseases (PIDs). Early diagnosis remains the mainstay in …
Deficiencias de anticuerpos en niños y adolescentes con infecciones recurrentes y/o graves
F Caballero, S Benegas, V Giménez… - Pediatría …, 2018 - scielo.iics.una.py
Introducción: Las deficiencias predominantes de anticuerpos (DPA) son inmunodeficiencias
primarias caracterizadas por hipogammaglobulinemia, una disminución de niveles séricos …
primarias caracterizadas por hipogammaglobulinemia, una disminución de niveles séricos …
Evaluation of IL-12RB1, IL-12B, CXCR-3 and IL-17a expression in cases affected by a non-healing form of cutaneous leishmaniasis: an observational study design
Introduction Seldom cutaneous leishmaniasis (CL) may present as a lasting and active
lesion (s), known as a non-healing form of CL (NHCL). Non-functional type 1 T helper (Th1) …
lesion (s), known as a non-healing form of CL (NHCL). Non-functional type 1 T helper (Th1) …